Enveric Biosciences (NASDAQ:ENVB) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Enveric Biosciences (NASDAQ:ENVB) from a sell rating to a hold rating in a research note published on Sunday morning.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Enveric Biosciences in a research report on Friday, July 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Enveric Biosciences presently has an average rating of “Sell”.

Enveric Biosciences Stock Up 3.5%

Shares of ENVB opened at $1.46 on Friday. The stock has a market cap of $6.54 million, a price-to-earnings ratio of -0.12 and a beta of 1.13. Enveric Biosciences has a 12 month low of $1.25 and a 12 month high of $17.64. The company has a 50-day moving average price of $1.41 and a two-hundred day moving average price of $2.01.

Enveric Biosciences (NASDAQ:ENVB) last posted its earnings results on Friday, August 14th. The company reported ($0.76) EPS for the quarter.

About Enveric Biosciences

Enveric Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety.